-
1
-
-
84899748354
-
Current pre-clinical and clinical advances in the BCR-ABL1-positive and-negative chronic myeloproliferative neoplasms
-
Mughal TI, Vannucchi AM, Soverini S, et al. Current pre-clinical and clinical advances in the BCR-ABL1-positive and-negative chronic myeloproliferative neoplasms. Haematologica 2014;99:797-803.
-
(2014)
Haematologica
, vol.99
, pp. 797-803
-
-
Mughal, T.I.1
Vannucchi, A.M.2
Soverini, S.3
-
2
-
-
0035810147
-
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
-
Druker B, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1042.
-
(2001)
N Engl J Med
, vol.344
, pp. 1031-1042
-
-
Druker, B.1
Talpaz, M.2
Resta, D.J.3
-
3
-
-
84902507360
-
Four-year (yr) follow-up of patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib or imatinib: Efficacy based on early response
-
Cortes J, Hochhaus A, Kim DW, et al. Four-year (yr) follow-up of patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib or imatinib: efficacy based on early response. Blood. 2013;122(Suppl. 1): Abstract 65.
-
(2013)
Blood
, vol.122
, pp. 65
-
-
Cortes, J.1
Hochhaus, A.2
Kim, D.W.3
-
4
-
-
84902484777
-
ENESTnd update: Nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and Sokal risk at diagnosis on long-term outcomes
-
Saglio G, Hochhaus A, Hughes T, et al. ENESTnd update: nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and Sokal risk at diagnosis on long-term outcomes. Blood 2013;122(Suppl. 1): Abstract 92.
-
(2013)
Blood
, vol.122
, pp. 92
-
-
Saglio, G.1
Hochhaus, A.2
Hughes, T.3
-
5
-
-
17844383458
-
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera
-
James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005;434:1144-1148.
-
(2005)
Nature
, vol.434
, pp. 1144-1148
-
-
James, C.1
Ugo, V.2
Le Couedic, J.P.3
-
6
-
-
77956696835
-
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis
-
Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-1127.
-
(2010)
N Engl J Med
, vol.363
, pp. 1117-1127
-
-
Verstovsek, S.1
Kantarjian, H.2
Mesa, R.A.3
-
7
-
-
84863393110
-
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
-
Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366:799-807.
-
(2012)
N Engl J Med
, vol.366
, pp. 799-807
-
-
Verstovsek, S.1
Mesa, R.A.2
Gotlib, J.3
-
8
-
-
84857837774
-
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
-
Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-798.
-
(2012)
N Engl J Med
, vol.366
, pp. 787-798
-
-
Harrison, C.1
Kiladjian, J.J.2
Al-Ali, H.K.3
-
9
-
-
84901714382
-
Integrated geneomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
-
Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Integrated geneomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 2014;123:e123-e133.
-
(2014)
Blood
, vol.123
, pp. e123-e133
-
-
Rampal, R.1
Al-Shahrour, F.2
Abdel-Wahab, O.3
-
10
-
-
84890372480
-
Somatic mutations of calreticulin in myeloproliferative neoplasms
-
Klampf T, Gisslinger H, Hanutyunyan A, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369:2379-2390.
-
(2013)
N Engl J Med
, vol.369
, pp. 2379-2390
-
-
Klampf, T.1
Gisslinger, H.2
Hanutyunyan, A.3
-
11
-
-
84890328032
-
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2
-
Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391-2405.
-
(2013)
N Engl J Med
, vol.369
, pp. 2391-2405
-
-
Nangalia, J.1
Massie, C.E.2
Baxter, E.J.3
-
12
-
-
84902589906
-
From Janus kinase 2 to calreticulin: The clinically relevant genomic landscape of myeloproliferative neoplasms
-
Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood 2014;123:3714-3719.
-
(2014)
Blood
, vol.123
, pp. 3714-3719
-
-
Cazzola, M.1
Kralovics, R.2
-
13
-
-
84902669989
-
Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F driven mouse model of myeloproliferative neoplasms
-
Duek A, Lundberg P, Shimizu T, et al. Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F driven mouse model of myeloproliferative neoplasms. Blood 2014;123 : 3943-3950.
-
(2014)
Blood
, vol.123
, pp. 3943-3950
-
-
Duek, A.1
Lundberg, P.2
Shimizu, T.3
-
14
-
-
32844461437
-
Why does CML evolve from a chronic phase to blast phase?
-
Mughal TI, Goldman JM. Why does CML evolve from a chronic phase to blast phase? Front Biosci 2006;1:198-208.
-
(2006)
Front Biosci
, vol.1
, pp. 198-208
-
-
Mughal, T.I.1
Goldman, J.M.2
-
15
-
-
52649131772
-
The natural history and treatment outcome of blast phase BCR-ABL-myeloproliferative neoplasms
-
Tam CS, Nussenzveig RM, Popat U, et al. The natural history and treatment outcome of blast phase BCR-ABL-myeloproliferative neoplasms. Blood 2008;112:1628-1637.
-
(2008)
Blood
, vol.112
, pp. 1628-1637
-
-
Tam, C.S.1
Nussenzveig, R.M.2
Popat, U.3
-
16
-
-
84878225843
-
Treatment outcomes following leukemic transformation in Ph-negative myeloproliferative neoplasms
-
Kennedy JA, Atenafu EG, Messner HA, et al. Treatment outcomes following leukemic transformation in Ph-negative myeloproliferative neoplasms. Blood 2013;121:2725-2733.
-
(2013)
Blood
, vol.121
, pp. 2725-2733
-
-
Kennedy, J.A.1
Atenafu, E.G.2
Messner, H.A.3
-
17
-
-
84861082246
-
Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome
-
Zhang SJ, RampalR, ManshouriT, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 2012;119:4480-4485.
-
(2012)
Blood
, vol.119
, pp. 4480-4485
-
-
Zhang, S.J.1
Rampal, R.2
Manshouri, T.3
-
18
-
-
84872522380
-
ADAR-1 promotes malignant progenitor programming in chronic myeloid leukemia
-
Jiang Q, Crews LA, Barrett CL, et al. ADAR-1 promotes malignant progenitor programming in chronic myeloid leukemia. Proc Natl Acad Sci USA 2013;110:1041-1046.
-
(2013)
Proc Natl Acad Sci USA
, vol.110
, pp. 1041-1046
-
-
Jiang, Q.1
Crews, L.A.2
Barrett, C.L.3
-
19
-
-
84938054376
-
Development of a murine model for leukemic transformation of myeloproliferative neoplasms for preclinical therapeutic studies
-
Rampal R, Pandey S, Abdel-Wahab O, et al. Development of a murine model for leukemic transformation of myeloproliferative neoplasms for preclinical therapeutic studies. Blood 2012;120(Suppl. 1): Abstract 808.
-
(2012)
Blood
, vol.120
, pp. 808
-
-
Rampal, R.1
Pandey, S.2
Abdel-Wahab, O.3
-
20
-
-
84898402032
-
The relationship of JAK2V617F and acquired UPD at chromosome 9p in polycythemia vera
-
Wang L, Swierczek SI, Lanikova L, et al. The relationship of JAK2V617F and acquired UPD at chromosome 9p in polycythemia vera. Leukemia 2014;28:938-941.
-
(2014)
Leukemia
, vol.28
, pp. 938-941
-
-
Wang, L.1
Swierczek, S.I.2
Lanikova, L.3
-
21
-
-
84898472976
-
Whole-exome sequencing of polycythemia vera revealed driver genes and somatic mutation shared by T cells and granulocytes
-
Wang L, Swierczek SI, Drummond J, et al. Whole-exome sequencing of polycythemia vera revealed driver genes and somatic mutation shared by T cells and granulocytes. Leukemia 2014;28: 935-938.
-
(2014)
Leukemia
, vol.28
, pp. 935-938
-
-
Wang, L.1
Swierczek, S.I.2
Drummond, J.3
-
22
-
-
84938143461
-
Order matters: Mutation order influences tumour evolution and stem cell potency by altering transcriptional consequences of the second mutation
-
EHA Abstract LBA2434
-
Kent D, Green AR. Order matters: mutation order influences tumour evolution and stem cell potency by altering transcriptional consequences of the second mutation. Haematologica 2014: EHA Abstract LBA2434.
-
(2014)
Haematologica
-
-
Kent, D.1
Green, A.R.2
-
23
-
-
70349256226
-
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes
-
Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-951.
-
(2009)
Blood
, vol.114
, pp. 937-951
-
-
Vardiman, J.W.1
Thiele, J.2
Arber, D.A.3
-
24
-
-
74049112732
-
Prodromal myeloproliferative neoplasms: The 2008 WHO classification
-
Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol 2008;85: 62-69.
-
(2008)
Am J Hematol
, vol.85
, pp. 62-69
-
-
Kvasnicka, H.M.1
Thiele, J.2
-
25
-
-
84875474755
-
JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis
-
Barosi G, Poletto V, Massa M, et al. JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis. PLoS One 2013;8:e59791.
-
(2013)
PLoS One
, vol.8
, pp. e59791
-
-
Barosi, G.1
Poletto, V.2
Massa, M.3
-
26
-
-
33745079673
-
Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: A forgotten pearl
-
Thiele J, Kvasnicka HM, Vardiman J. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. Best Pract Res Clin Haematol 2006;19:413-437.
-
(2006)
Best Pract Res Clin Haematol
, vol.19
, pp. 413-437
-
-
Thiele, J.1
Kvasnicka, H.M.2
Vardiman, J.3
-
27
-
-
16344385524
-
Standardization of bone marrow features-does it work in hematopathology for histological discrimination of different disease patterns?
-
Thiele J, Kvasnicka HM, Diehl V. Standardization of bone marrow features-does it work in hematopathology for histological discrimination of different disease patterns? Histol Histopathol 2005; 20:633-644.
-
(2005)
Histol Histopathol
, vol.20
, pp. 633-644
-
-
Thiele, J.1
Kvasnicka, H.M.2
Diehl, V.3
-
28
-
-
79957611312
-
Essential thrombo-cythemia versus early primary myelofibrosis: A multicenter study to validate the WHO classification
-
Thiele J, Kvasnicka HM, Mullauer L, et al. Essential thrombo-cythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 2011;117:5710-5718.
-
(2011)
Blood
, vol.117
, pp. 5710-5718
-
-
Thiele, J.1
Kvasnicka, H.M.2
Mullauer, L.3
-
29
-
-
84892882972
-
Masked polycythemia vera (mPV): Results of an international study
-
Barbui T, Thiele J, Gisslinger H, et al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol 2014;89: 52-54.
-
(2014)
Am J Hematol
, vol.89
, pp. 52-54
-
-
Barbui, T.1
Thiele, J.2
Gisslinger, H.3
-
30
-
-
84873515382
-
Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up
-
Ejerblad E, Kvasnicka HM, Thiele J, et al. Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up. Hematology 2013; 18:8-13.
-
(2013)
Hematology
, vol.18
, pp. 8-13
-
-
Ejerblad, E.1
Kvasnicka, H.M.2
Thiele, J.3
-
31
-
-
84876515240
-
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: The ANAHYDRET study, a randomized controlled trial
-
Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial. Blood 2013; 121:1720-1728.
-
(2013)
Blood
, vol.121
, pp. 1720-1728
-
-
Gisslinger, H.1
Gotic, M.2
Holowiecki, J.3
-
32
-
-
84938143462
-
European LeukemiaNet (ELN) consensus criteria for therapy response based on bone marrow features in patients with myelofibrosis
-
(in press)
-
Kvasnicka HM, Thiele J, Orazi A, et al. European LeukemiaNet (ELN) consensus criteria for therapy response based on bone marrow features in patients with myelofibrosis. J Clin Oncol to Leukemia (in press).
-
J Clin Oncol to Leukemia
-
-
Kvasnicka, H.M.1
Thiele, J.2
Orazi, A.3
-
33
-
-
0037114625
-
Polycythemia vera: Myths, mechanisms, and management
-
Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002;100:4272-4290.
-
(2002)
Blood
, vol.100
, pp. 4272-4290
-
-
Spivak, J.L.1
-
34
-
-
84893964717
-
Masked polycythemia vera diagnosed according to WHO and BCSH classification
-
Barbui T, Thiele J, Carobbio A, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol 2014;89:199-202.
-
(2014)
Am J Hematol
, vol.89
, pp. 199-202
-
-
Barbui, T.1
Thiele, J.2
Carobbio, A.3
-
35
-
-
84859643082
-
Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms
-
Deshpande A, Reddy MM, Schade GOM, et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia 2012;26:708-715.
-
(2012)
Leukemia
, vol.26
, pp. 708-715
-
-
Deshpande, A.1
Reddy, M.M.2
Schade, G.O.M.3
-
36
-
-
84899696697
-
Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors
-
Marty C, Saint-Martin C, Pecquet C, et al. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood 2014;123:1372-1383.
-
(2014)
Blood
, vol.123
, pp. 1372-1383
-
-
Marty, C.1
Saint-Martin, C.2
Pecquet, C.3
-
37
-
-
84898990827
-
Molecular pathways: Molecular basis for sensitivity and resistance to JAK kinase inhibitors
-
Meyer S, Levine R. Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res 2014;20:2051-2059.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 2051-2059
-
-
Meyer, S.1
Levine, R.2
-
38
-
-
84924809368
-
Clinical resistance to ruxolitinib is more frequent in patients without MPN-associated mutations and is rarely due to mutations in the JAK2 kinase drug-binding domain
-
Andreoli A, Verger E, Robin M, et al. Clinical resistance to ruxolitinib is more frequent in patients without MPN-associated mutations and is rarely due to mutations in the JAK2 kinase drug-binding domain. Blood 2013;122(Supp. 1): Abstract 1591.
-
(2013)
Blood
, vol.122
, pp. 1591
-
-
Andreoli, A.1
Verger, E.2
Robin, M.3
-
39
-
-
84856932936
-
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition
-
Weigert O, Lane A, Bird J, et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med 2012;209:259-273.
-
(2012)
J Exp Med
, vol.209
, pp. 259-273
-
-
Weigert, O.1
Lane, A.2
Bird, J.3
-
40
-
-
84865735256
-
Heterdimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
-
Koppikar P, Bhagwat N, Kilpivaara O, et al. Heterdimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012;489:155-159.
-
(2012)
Nature
, vol.489
, pp. 155-159
-
-
Koppikar, P.1
Bhagwat, N.2
Kilpivaara, O.3
-
41
-
-
84891303523
-
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
-
Cervantes F, Vannucchi AM, Kiladjian J-J, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122:4047-4053.
-
(2013)
Blood
, vol.122
, pp. 4047-4053
-
-
Cervantes, F.1
Vannucchi, A.M.2
Kiladjian, J.-J.3
-
42
-
-
84901007488
-
Long-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT-I
-
Verstovsek S, Mesa R, Gotlib J, et al. Long-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT-I. Blood 2013;122(Suppl. 1): Abstract 396.
-
(2013)
Blood
, vol.122
, pp. 396
-
-
Verstovsek, S.1
Mesa, R.2
Gotlib, J.3
-
43
-
-
84897566182
-
Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy
-
Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy. Blood 2013;122(Suppl. 1): Abstract 4055.
-
(2013)
Blood
, vol.122
, pp. 4055
-
-
Kvasnicka, H.M.1
Thiele, J.2
Bueso-Ramos, C.E.3
-
44
-
-
84894237348
-
Results of a randomized, double-blind, placebo-controlled phase III study (Jakarta) of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (MF)
-
Harrison CN, Cortes JE, Cervantes F, Mesa et al. Results of a randomized, double-blind, placebo-controlled phase III study (Jakarta) of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (MF). Blood 2013;122(Suppl. 1): Abstract 393.
-
(2013)
Blood
, vol.122
, pp. 393
-
-
Harrison, C.N.1
Cortes, J.E.2
Cervantes, F.3
Mesa4
-
45
-
-
84901017205
-
Symptom burden and health-related quality of life (HRQoL) in patients with myelofibrosis (MF) treated with fedratinib (SAR302503) in a phase III study (Jakarta)
-
MesaR, Cortes JE, Cervantes F, et al. Symptom burden and health-related quality of life (HRQoL) in patients with myelofibrosis (MF) treated with fedratinib (SAR302503) in a phase III study (Jakarta). Blood 2013;122(Suppl. 1): Abstract 4061.
-
(2013)
Blood
, vol.122
, pp. 4061
-
-
Mesa, R.1
Cortes, J.E.2
Cervantes, F.3
-
46
-
-
84896937999
-
Efficacy and safety of fedratinib (SAR302503/TG101348) in patients with intermediate-or high-risk myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF previously treated with ruxolitinib: Interim results from a phase II study (Jakarta-2)
-
Harrison C, Schaap NP, Zweegman S, et al. Efficacy and safety of fedratinib (SAR302503/TG101348) in patients with intermediate-or high-risk myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF previously treated with ruxolitinib: interim results from a phase II study (Jakarta-2). Blood 2013;122(Suppl. 1): Abstract 661.
-
(2013)
Blood
, vol.122
, pp. 661
-
-
Harrison, C.1
Schaap, N.P.2
Zweegman, S.3
-
47
-
-
84907912086
-
The Janus kinase 2 inhibtor fedratinib inhibits thiamine uptake: A putative mechanism for the onset of Wernicke's encephalopathy
-
Zhang Q, Zhang Y, Diamond S, et al. The Janus kinase 2 inhibtor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy. Drug Metab Dispos 2014;42: 1656-1662.
-
(2014)
Drug Metab Dispos
, vol.42
, pp. 1656-1662
-
-
Zhang, Q.1
Zhang, Y.2
Diamond, S.3
-
48
-
-
84900870280
-
Pacritinib, a dual JAK2/FLT3 inhibitor: An integrated efficacy and safety analysis of phase II trial data in patients with primary and secondary myelofibrosis (MF) and platelet counts < 100,000/liI
-
Dean JP, Cernohous P, Komrokji RS, et al. Pacritinib, a dual JAK2/FLT3 inhibitor: an integrated efficacy and safety analysis of phase II trial data in patients with primary and secondary myelofibrosis (MF) and platelet counts < 100,000/liI. Blood 2013;122(Suppl. 1): Abstract 395.
-
(2013)
Blood
, vol.122
, pp. 395
-
-
Dean, J.P.1
Cernohous, P.2
Komrokji, R.S.3
-
49
-
-
84878951826
-
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
-
Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013;27:1322-1327.
-
(2013)
Leukemia
, vol.27
, pp. 1322-1327
-
-
Pardanani, A.1
Laborde, R.R.2
Lasho, T.L.3
-
50
-
-
84896985472
-
Phase i study of LY2784544, a JAK2 selective inhibitor, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET)
-
Verstovsek S, Mesa RA, Salama ME, et al. Phase I study of LY2784544, a JAK2 selective inhibitor, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). Blood 2013;122(Suppl. 1): Abstract 665.
-
(2013)
Blood
, vol.122
, pp. 665
-
-
Verstovsek, S.1
Mesa, R.A.2
Salama, M.E.3
-
51
-
-
84896941348
-
BMS-911543, a selective JAK2 inhibitor: A multicenter phase 1/2a study in myelofibrosis
-
Pardanani A, Roberts AW, Seymour JF, et al. BMS-911543, a selective JAK2 inhibitor: a multicenter phase 1/2a study in myelofibrosis. Blood 2013;122(Suppl. 1): Abstract 664.
-
(2013)
Blood
, vol.122
, pp. 664
-
-
Pardanani, A.1
Roberts, A.W.2
Seymour, J.F.3
-
52
-
-
84896917435
-
An open-label, phase II study of the JAK1 inhibitor INCB039110 in patients with myelofibrosis
-
Mascarenhas J, Talpaz M, Gupta V, et al. An open-label, phase II study of the JAK1 inhibitor INCB039110 in patients with myelofibrosis. Blood 2013;122(Suppl. 1): Abstract 663.
-
(2013)
Blood
, vol.122
, pp. 663
-
-
Mascarenhas, J.1
Talpaz, M.2
Gupta, V.3
-
53
-
-
84897000773
-
Imetelstat, a telomerase inhibitor, induces morphologic and molecular remissions in myelofibrosis and reversal of bone marrow fibrosis
-
Tefferi A, Begna K, Laborde RR, et al. Imetelstat, a telomerase inhibitor, induces morphologic and molecular remissions in myelofibrosis and reversal of bone marrow fibrosis. Blood 2013; 122(Suppl. 1): Abstract 662.
-
(2013)
Blood
, vol.122
, pp. 662
-
-
Tefferi, A.1
Begna, K.2
Laborde, R.R.3
-
54
-
-
84927968894
-
Does anything work for anemia in myelofibrosis?
-
Birgegard G. Does anything work for anemia in myelofibrosis? Best Pract Res Clin Haematol 2014;27:175-185.
-
(2014)
Best Pract Res Clin Haematol
, vol.27
, pp. 175-185
-
-
Birgegard, G.1
-
55
-
-
84892718446
-
Deep molecular response in chronic myeloid leukemia: The new goal therapy?
-
Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal therapy? Clin Cancer Res 2014;20:310-322.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 310-322
-
-
Mahon, F.X.1
Etienne, G.2
-
56
-
-
84880790088
-
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts
-
Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439-4442.
-
(2013)
Blood
, vol.121
, pp. 4439-4442
-
-
Experts in Chronic Myeloid Leukemia1
-
57
-
-
84881298446
-
EuropeanLeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
-
BaccaraniM, DeiningerMW, RostiG, et al. EuropeanLeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872-884.
-
(2013)
Blood
, vol.122
, pp. 872-884
-
-
Baccarani, M.1
Deininger, M.W.2
Rosti, G.3
-
58
-
-
84905387521
-
Molecular response in CML: Where is the bar?
-
Baccarani M, Soverini S. Molecular response in CML: where is the bar? Blood 2014;124:469-471.
-
(2014)
Blood
, vol.124
, pp. 469-471
-
-
Baccarani, M.1
Soverini, S.2
-
59
-
-
84897574239
-
Deep molecular response is reached by the majority of patients treated with imatinb, predicts survival, and is achieved more quickly by optimized high-dose imatinib: Results from the randomized CML-Study IV
-
Hehlmann R, Muller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinb, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV. J Clin Oncol 2014;32:415-423.
-
(2014)
J Clin Oncol
, vol.32
, pp. 415-423
-
-
Hehlmann, R.1
Muller, M.C.2
Lauseker, M.3
-
60
-
-
84896622957
-
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors
-
Kantarjian HM, Cortes JE, Kim DW, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood 2014:123:1309-1318.
-
(2014)
Blood
, vol.123
, pp. 1309-1318
-
-
Kantarjian, H.M.1
Cortes, J.E.2
Kim, D.W.3
-
61
-
-
52649104330
-
Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease
-
Agarwal A, Bumm TG, Corbin AS, et al. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood 2008;112:1960-1970.
-
(2008)
Blood
, vol.112
, pp. 1960-1970
-
-
Agarwal, A.1
Bumm, T.G.2
Corbin, A.S.3
-
62
-
-
84938143463
-
P27 and leukemia: Cell cycle and beyond
-
Sep 10. [Epub ahead of print]
-
Roy A, Banerjee S. p27 and leukemia: cell cycle and beyond. J Cell Physiol 2014 Sep 10. [Epub ahead of print]
-
(2014)
J Cell Physiol
-
-
Roy, A.1
Banerjee, S.2
-
63
-
-
85027918531
-
Novel myelofibrosis treatment strategies: Potential partners for combination therapies
-
Jun 3. [Epub ahead of print]
-
Stein BL, Swords R, Hochhaus A, et al. Novel myelofibrosis treatment strategies: potential partners for combination therapies. Leukemia 2014 Jun 3. [Epub ahead of print]
-
(2014)
Leukemia
-
-
Stein, B.L.1
Swords, R.2
Hochhaus, A.3
|